Phase III, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Have Been Previously Exposed to TNF Inhibitors
Phase III, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Have Been Previously Exposed to TNF Inhibitors
This Phase III, double-blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission compared with placebo in the treatment of participants with moderately to severely active ulcerative colitis (UC) who have been previously exposed to TNF inhibitors.
Inclusion Criteria:
Exclusion Criteria:
Lakewood, Colorado 80215, United States
Ann Arbor, Michigan 48109, United States
Rio de Janeiro, Rio de Janeiro 21941-913, Brazil
Botucatu, São Paulo 18618-970, Brazil
Edmonton, Alberta T6G 2X8, Canada
Halifax, Nova Scotia B3H 1V7, Canada
Ústí nad Labem, 401 13, Czechia
Amiens Cedex01, 80054, France
Freiburg im Breisgau, 79106, Germany
Hanover, 30625, Germany
Budapest, H-1077, Hungary
Miskolc, 3526, Hungary
Petach Tiqwa, 49100, Israel
Milan, Lombardy, Italy
NL -nijmegen, 6525 GA, Netherlands
Warsaw, 02-781, Poland
Bern, 3012, Switzerland